Nicholas Investment Partners’s Vaxcyte PCVX Stock Holding History

Nicholas Investment Partners’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-116,229	Closed	-$4.39M	–	226
2025 Q1	$4.39M	Buy	116,229 +15,922	+16%	+$1.27M	0.45%	92
2024 Q4	$8.21M	Buy	100,307 +18,424	+23%	+$1.83M	0.72%	40
2024 Q3	$9.36M	Sell	81,883 -5,347	-6%	-$482K	0.86%	33
2024 Q2	$6.59M	Buy	87,230 +1,586	+2%	+$108K	0.68%	44
2024 Q1	$5.85M	Sell	85,644 -25,079	-23%	-$1.74M	0.6%	56
2023 Q4	$6.95M	Sell	110,723 -349,285	-76%	-$18.1M	0.81%	33
2023 Q3	$23.5M	Sell	460,008 -156	-0%	-$7.7K	1.75%	16
2023 Q2	$23M	Buy	460,164 +26,364	+6%	+$1.25M	1.57%	20
2023 Q1	$16.3M	Buy	433,800 +310,478	+252%	+$13.2M	1.24%	29
2022 Q4	$5.91M	Buy	+123,322	New	+$4.84M	0.52%	61

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Nicholas Investment Partners's PCVX Position: Q2 2025 in Review

Nicholas Investment Partners sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 116,229 shares — an estimated $4.39M sold.

Nicholas Investment Partners first reported a position in PCVX in Q4 2022 and held it in 10 quarters. The position peaked at $23.5M in Q3 2023. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

Nicholas Investment Partners reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
Nicholas Investment Partners sold 116,229 Vaxcyte shares in Q2 2025, an estimated $4.39M.
Nicholas Investment Partners first reported a position in Vaxcyte in Q4 2022 and held it in 10 quarters.
Nicholas Investment Partners's Vaxcyte position peaked at $23.5M in Q3 2023.
294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Nicholas Investment Partners's 13F filing for Q2 2025, filed 14 Aug 2025.